Short answer
Organon & Co (OGN) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.6B (down 1.7% year over year) with net income of $164M.
Q3 2026 key financials · XBRL
- Revenue
- $1.6B
- −1.7% YoY · +1.0% QoQ
- Net income
- $164M
- +2.5% YoY · +51.9% QoQ
- Gross margin
- 55.2%
- EPS (diluted)
- $0.61
- +0.0% YoY · +52.5% QoQ
Source: XBRL data from the Organon & Co (OGN) Q3 2026 10-Q on SEC EDGAR. USD.
Organon & Co Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.574B, down 2% YoY, including approximately $12M favorable foreign exchange impact
- Quarterly gross margin 61.2% vs 59.6% YoY, based on gross profit of $965M and revenue of $1.574B
- Best product: Hadlima sales up 35% YoY; worst: Ontruzant sales down 77%
- Cash $1.46B; nine-month operating cash flow $702M vs $559M YoY
- Headwinds: supply constraints, Nexplanon demand weakness, VBP expected to continue affecting general medicines for several quarters
Risk Factors
- Newly added patent risk: four Vtama generic ANDAs filed, targeting twelve or nine Orange Book patents expiring 2036–2039
- Regulatory risk: SEC investigation into Nexplanon wholesaler sales, following Organon’s October 26, 2025 voluntary disclosure
- Legal risk: third stockholder derivative suit filed September 19, 2026, adding allegations concerning capital allocation, debt reduction and Nexplanon
- Operational risk: Samsung returned Ontruzant and Aybintio commercialization rights in specified ex-U.S. markets, with transitions through 2029
- Financial risk: $8,554 million debt principal, including $3,483 million due in 2028 and average maturity of 3.8 years
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.